▲ Peaking
Business
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
Kyverna's miv-cel data resets conversation in autoimmune CAR-T therapy.
Autoimmune
4 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Autoimmune
This hub groups 4 separate news trends connected to Autoimmune, spanning August 31, 2026 through September 25, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 28 article observations and 26 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Novartis and Bristol Myers have halted autoimmune CAR-T trials after three patient deaths.
◼ Archived
Business
Lilly snags another Massachusetts biotech as local headcount surges past 1,400
Eli Lilly's $2.88 billion bid for Merida Biosciences marks its 13th 2026 acquisition, swelling Massachusetts biotech staffing.
◼ Archived
Business
🔮 fades ✓
Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies
Eli Lilly's $2.88 billion acquisition of Merida Biosciences is poised to reshape the autoimmune disease treatment landscape.